A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer

NCT07586449 | Not Yet Recruiting

• 1 other identifier: IRB-2026-348 (IIT)
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in gynecologic malignancies, the majority of patients have advanced diseases at the time of diagnosis. This observational study is to evaluate the safety and efficacy of senaparib in ovarian cancer patients under real conditions, especially in various subgroups of ovarian cancer patients, in order to provide information about treatment modes for ovarian cancer patients in real-world diagnosis and treatment。

Conditions

Ovarian Cancer (OvCa)

Keywords

senaparib; real word study; ovarian cancer

Outcome Measures

Primary Outcomes (1)

• Incidence and severity of Treatment-Related Adverse Events (TRAEs) according to NCI CTCAE v5.0

  Incidence and severity of Treatment-Related Adverse Events (TRAEs) as assessed by the investigator.

  30 days after the last dose of fluzoparib

Secondary Outcomes (3)

• treatment patterns of senaparib

  2 years

• Progression free survival (PFS)

  6 years

• overall survival (OS)

  6 years

Interventions

Senaparib capsules(20mg) DRUG

senaparib monotherapy or combination therapy

Eligibility Criteria

• Age: 18 Years+
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer had decided to use senaparib at the time of enrollment in this study

You may qualify if:

• Sign informed consent and voluntarily join the study;
• Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer diagnosed by histology or cytology;
• ≥ 18 years old;
• The investigator determined that the patient could receive senaparib monotherapy or combination therapy;
• For patients with fertility, effective contraceptive methods should be used during the study period and within 90 days after the last administration of senaparib

You may not qualify if:

• There is evidence that the patient is a pregnant or lactating woman;
• Participating in any research with intervention measures other than routine -clinical practice;

Sponsors & Collaborators

• Zhejiang Cancer Hospital: lead

Study Sites (1)

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

Location

MeSH Terms

Conditions

Ovarian Neoplasms

Interventions

senaparib

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders

Central Study Contacts

Tao Zhu

CONTACT

+86 138 5806 5156; zhutao@zjcc.org.cn

Ying Li Zhang

CONTACT

+86152 6853 0651

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 6 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: May 8, 2026
• First Posted: May 14, 2026
• Study Start: June 10, 2026
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2030
• Last Updated: May 14, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)